Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Ursodeoxycholic acid changes frequency of adverse events ( compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Proportion with adverse events · lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dropouts due to adverse events · alcohol use disorder
Summary of findings table ‐ Baclofen showed no clear difference in dropouts due to adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events ‐ total · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events ‐ total compared with placebo or standard care alone (moderate certainty).
1 finding from 1 review
Side effects or other adverse events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Side effects or other adverse events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (during · children or adults with Types I or II HAE
Berotralstat showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether plasma‐derived C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether recombinant human C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether avoralstat changes serious adverse events (during compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
Lanadelumab showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).
1 finding from 1 review
Adverse events (any type) and safety of sealant · Children and/or adults with permanent or primary teeth, vital (sensitive) pulps, and cavitated or dentine carious lesions conventionally…
The review found no eligible studies for this question.
1 finding from 1 review
Dropouts due to adverse events · adults receiving mechanical ventilation for at least 48 hours
Topical plus systemic prophylaxis showed no clear difference in dropouts due to adverse events compared with placebo or no treatment (low certainty).
1 finding from 1 review
Overall adverse events 5 weeks · adults with seasonal affective disorder
It is very uncertain whether fluoxetine changes overall adverse events 5 weeks compared with placebo (very low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Sotrovimab may leads to lower adverse events: grades 3 and 4 compared with placebo (low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Regdanvimab showed no clear difference in adverse events: grades 3 and 4 compared with placebo (low certainty).
1 finding from 1 review
Rate of serious adverse events · adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)
2 findings from 1 review
Rate of serious adverse events · patients with chronic heart failure with preserved ejection fraction
2 findings from 1 review